0.014110
0.000000
0.000000
0.000000
0.011073
0.000000
0.000000
0.000000
0.011307
0.00000
0.00000
0.00000
Roe, S.M.
Prodromou, C.
Pearl, L.H.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
8
90.00
90.00
90.00
70.870
90.310
88.440
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
H2 O
18.015
WATER
non-polymer
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
C16 H13 Cl N2 O4 S
364.803
4-CHLORO-6-[5-(3,4-DIMETHOXYPHENYL)-1,2,3-THIADIAZOL-4-YL]BENZENE-1,3-DIOL
non-polymer
US
Plos One
1932-6203
7
44642
10.1371/JOURNAL.PONE.0044642
22984537
Co-Crystalization and in Vitro Biological Characterization of 5-Aryl-4-(5-Substituted-2-4-Dihydroxyphenyl)-1,2,3-Thiadiazole Hsp90 Inhibitors.
2012
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
100
1
CCD
2009-05-27
ADSC CCD
SINGLE WAVELENGTH
M
x-ray
1
0.9796
1.0
I02
Diamond
0.9796
SYNCHROTRON
DIAMOND BEAMLINE I02
25856.082
HEAT SHOCK PROTEIN HSP 90-ALPHA
N-TERMINAL DOMAIN, RESIDUES 1-229
1
man
polymer
364.803
4-CHLORO-6-[5-(3,4-DIMETHOXYPHENYL)-1,2,3-THIADIAZOL-4-YL]BENZENE-1,3-DIOL
1
syn
non-polymer
18.015
water
107
nat
water
HEAT SHOCK 86 KDA, HSP 86, HSP86, RENAL CARCINOMA ANTIGEN NY-REN-38, HSP90
no
no
MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINL
IPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQY
AWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKE
MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINL
IPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQY
AWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKE
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
HUMAN
sample
9606
HOMO SAPIENS
562
ESCHERICHIA COLI
1
2.83
57
NONE
7
pH 7
repository
Initial release
Database references
1
0
2012-05-16
1
1
2012-09-26
STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS.
NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN
HUMAN HSP90 IN COMPLEX WITH 17-DESMETHOXY-17-N,N- DIMETHYLAMINOETHYLAMINO-GELDANAMYCIN
ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
STRUCTURE-BASED DISCOVERY OF A NEW CLASS OF HSP90 INHIBITORS
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H- PYRAZOL-3-YL)-BENZENE-1,2-DIOL
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2- FLUORO-9-PENT-9H-PURIN-6-YLAMINE
HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5- TRIMETHOXY-BENZYL)-2-FLUORO-9-PENT-4-YLNYL-9H-PURIN -6-YLAMINE
CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED WITHDIHYDROXYPHENYLPYRAZOLES
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4- CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE
STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS.
4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE
STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND
STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATERSOLUBLE INHIBITOR PU-H71
STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND
STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND
HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY- BENZYL)-2-FLUORO-9H-PURIN-6-YLAMINE
STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT WATERSOLUBLE INHIBITOR PU-H64
HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5- TRIMETHOXY-BENZYL)-9-PENT-4-YLNYL-9H-PURIN-6-YLAMINE
STRUCTURE-ACTIVITY RELATIONSHIPS IN PURINE-BASED INHIBITOR BINDING TO HSP90 ISOFORMS
STRUCTURE OF HSP90 WITH AN INHIBITOR BOUND
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND
HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(4-METHOXY-BENZYL )-9H-PURIN-6-YLAMINE
STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4- CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE
ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE
HUMAN HSP90 WITH 4-(4-(2,3-DIHYDRO-BENZOL(1,4) DIOXIN-6-YL)-5-METHYL-1H-PYRAZOL-3-YL)-6-ETHYL- BENZENE-1,3-DIOL
HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5- YLMETHYL-9-BUTYL-9H-PURIN-6-YLAMINE
HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "OPEN" CONFORMATION
HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG
STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS.
HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3-TRIMETHOXY- BENZYL)-9H-PURIN-6YLAMINE
ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE
SOLUTION STRUCTURE OF THE TPR DOMAIN FROM PROTEIN PHOSPHATASE 5 IN COMPLEX WITH HSP90 DERIVED PEPTIDE
INHIBITION OF THE HSP90 MOLECULAR CHAPERONE IN VITRO AND IN VIVO BY NOVEL, SYNTHETIC, POTENT RESORCINYLIC PYRAZOLE, ISOXAZOLE AMIDE ANALOGS
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE
STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND
NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "CLOSED" CONFORMATION
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND
HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2- FLUORO-9H-PURIN-6-YLAMINE
HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4- METHANESULPHONYL-BENZYL)-PIERAZIN-1-YL)-1H-PYRAZOL-3- YL)-BENZENE-1,3-DIOL
STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND
STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND
STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND
STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND
HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2-CHLORO-3,4,5 -TRIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE
ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE
STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3,4,5-TRIMETHOXY -BENZYL)-9H-PURIN-6-YLAMINE
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED WITHDIHYDROXYPHENYLPYRAZOLES
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
CRYSTAL STRUCTURE OF THE CHIP U-BOX E3 UBIQUITIN LIGASE
HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5- YLMETHYL-9-BUTYL-2-FLUORO-9H-PURIN-6-YLAMINE
HUMAN HSP90 WITH 5-(5-CHLORO-2,4-DIHYDROXY-PHENYL)- 4-PIPERAZIN-1-YL-2H-PYRAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE
ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
CRYSTAL STRUCTURES OF HUMAN HSP90ALPHA COMPLEXED WITHDIHYDROXYPHENYLPYRAZOLES
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY- BENZYL)-9H-PURIN-6-YLAMINE
GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN-BINDING DOMAIN
HSP90 ALPHA ATPASE DOMAIN WITH BOUND SMALL MOLECULE FRAGMENT
HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING
PDBE
Y
PDBE
2011-05-10
REL
YI5
4-CHLORO-6-[5-(3,4-DIMETHOXYPHENYL)-1,2,3-THIADIAZOL-4-YL]BENZENE-1,3-DIOL
HOH
water
4-CHLORO-6-[5-(3,4-DIMETHOXYPHENYL)-1,2,3-THIADIAZOL-4-
YL]BENZENE-1,3-DIOL (YI5).
YI5
1226
2
YI5
YI5
1226
A
HOH
2001
3
HOH
HOH
2001
A
HOH
2002
3
HOH
HOH
2002
A
HOH
2003
3
HOH
HOH
2003
A
HOH
2004
3
HOH
HOH
2004
A
HOH
2005
3
HOH
HOH
2005
A
HOH
2006
3
HOH
HOH
2006
A
HOH
2007
3
HOH
HOH
2007
A
HOH
2008
3
HOH
HOH
2008
A
HOH
2009
3
HOH
HOH
2009
A
HOH
2010
3
HOH
HOH
2010
A
HOH
2011
3
HOH
HOH
2011
A
HOH
2012
3
HOH
HOH
2012
A
HOH
2013
3
HOH
HOH
2013
A
HOH
2014
3
HOH
HOH
2014
A
HOH
2015
3
HOH
HOH
2015
A
HOH
2016
3
HOH
HOH
2016
A
HOH
2017
3
HOH
HOH
2017
A
HOH
2018
3
HOH
HOH
2018
A
HOH
2019
3
HOH
HOH
2019
A
HOH
2020
3
HOH
HOH
2020
A
HOH
2021
3
HOH
HOH
2021
A
HOH
2022
3
HOH
HOH
2022
A
HOH
2023
3
HOH
HOH
2023
A
HOH
2024
3
HOH
HOH
2024
A
HOH
2025
3
HOH
HOH
2025
A
HOH
2026
3
HOH
HOH
2026
A
HOH
2027
3
HOH
HOH
2027
A
HOH
2028
3
HOH
HOH
2028
A
HOH
2029
3
HOH
HOH
2029
A
HOH
2030
3
HOH
HOH
2030
A
HOH
2031
3
HOH
HOH
2031
A
HOH
2032
3
HOH
HOH
2032
A
HOH
2033
3
HOH
HOH
2033
A
HOH
2034
3
HOH
HOH
2034
A
HOH
2035
3
HOH
HOH
2035
A
HOH
2036
3
HOH
HOH
2036
A
HOH
2037
3
HOH
HOH
2037
A
HOH
2038
3
HOH
HOH
2038
A
HOH
2039
3
HOH
HOH
2039
A
HOH
2040
3
HOH
HOH
2040
A
HOH
2041
3
HOH
HOH
2041
A
HOH
2042
3
HOH
HOH
2042
A
HOH
2043
3
HOH
HOH
2043
A
HOH
2044
3
HOH
HOH
2044
A
HOH
2045
3
HOH
HOH
2045
A
HOH
2046
3
HOH
HOH
2046
A
HOH
2047
3
HOH
HOH
2047
A
HOH
2048
3
HOH
HOH
2048
A
HOH
2049
3
HOH
HOH
2049
A
HOH
2050
3
HOH
HOH
2050
A
HOH
2051
3
HOH
HOH
2051
A
HOH
2052
3
HOH
HOH
2052
A
HOH
2053
3
HOH
HOH
2053
A
HOH
2054
3
HOH
HOH
2054
A
HOH
2055
3
HOH
HOH
2055
A
HOH
2056
3
HOH
HOH
2056
A
HOH
2057
3
HOH
HOH
2057
A
HOH
2058
3
HOH
HOH
2058
A
HOH
2059
3
HOH
HOH
2059
A
HOH
2060
3
HOH
HOH
2060
A
HOH
2061
3
HOH
HOH
2061
A
HOH
2062
3
HOH
HOH
2062
A
HOH
2063
3
HOH
HOH
2063
A
HOH
2064
3
HOH
HOH
2064
A
HOH
2065
3
HOH
HOH
2065
A
HOH
2066
3
HOH
HOH
2066
A
HOH
2067
3
HOH
HOH
2067
A
HOH
2068
3
HOH
HOH
2068
A
HOH
2069
3
HOH
HOH
2069
A
HOH
2070
3
HOH
HOH
2070
A
HOH
2071
3
HOH
HOH
2071
A
HOH
2072
3
HOH
HOH
2072
A
HOH
2073
3
HOH
HOH
2073
A
HOH
2074
3
HOH
HOH
2074
A
HOH
2075
3
HOH
HOH
2075
A
HOH
2076
3
HOH
HOH
2076
A
HOH
2077
3
HOH
HOH
2077
A
HOH
2078
3
HOH
HOH
2078
A
HOH
2079
3
HOH
HOH
2079
A
HOH
2080
3
HOH
HOH
2080
A
HOH
2081
3
HOH
HOH
2081
A
HOH
2082
3
HOH
HOH
2082
A
HOH
2083
3
HOH
HOH
2083
A
HOH
2084
3
HOH
HOH
2084
A
HOH
2085
3
HOH
HOH
2085
A
HOH
2086
3
HOH
HOH
2086
A
HOH
2087
3
HOH
HOH
2087
A
HOH
2088
3
HOH
HOH
2088
A
HOH
2089
3
HOH
HOH
2089
A
HOH
2090
3
HOH
HOH
2090
A
HOH
2091
3
HOH
HOH
2091
A
HOH
2092
3
HOH
HOH
2092
A
HOH
2093
3
HOH
HOH
2093
A
HOH
2094
3
HOH
HOH
2094
A
HOH
2095
3
HOH
HOH
2095
A
HOH
2096
3
HOH
HOH
2096
A
HOH
2097
3
HOH
HOH
2097
A
HOH
2098
3
HOH
HOH
2098
A
HOH
2099
3
HOH
HOH
2099
A
HOH
2100
3
HOH
HOH
2100
A
HOH
2101
3
HOH
HOH
2101
A
HOH
2102
3
HOH
HOH
2102
A
HOH
2103
3
HOH
HOH
2103
A
HOH
2104
3
HOH
HOH
2104
A
HOH
2105
3
HOH
HOH
2105
A
HOH
2106
3
HOH
HOH
2106
A
HOH
2107
3
HOH
HOH
2107
A
n
1
1
A
n
2
2
A
n
3
3
A
n
4
4
A
n
5
5
A
n
6
6
A
n
7
7
A
n
8
8
A
n
9
9
A
n
10
10
A
n
11
11
A
n
12
12
A
n
13
13
A
n
14
14
A
n
15
15
A
GLU
16
n
16
GLU
16
A
VAL
17
n
17
VAL
17
A
GLU
18
n
18
GLU
18
A
THR
19
n
19
THR
19
A
PHE
20
n
20
PHE
20
A
ALA
21
n
21
ALA
21
A
PHE
22
n
22
PHE
22
A
GLN
23
n
23
GLN
23
A
ALA
24
n
24
ALA
24
A
GLU
25
n
25
GLU
25
A
ILE
26
n
26
ILE
26
A
ALA
27
n
27
ALA
27
A
GLN
28
n
28
GLN
28
A
LEU
29
n
29
LEU
29
A
MET
30
n
30
MET
30
A
SER
31
n
31
SER
31
A
LEU
32
n
32
LEU
32
A
ILE
33
n
33
ILE
33
A
ILE
34
n
34
ILE
34
A
ASN
35
n
35
ASN
35
A
THR
36
n
36
THR
36
A
PHE
37
n
37
PHE
37
A
TYR
38
n
38
TYR
38
A
SER
39
n
39
SER
39
A
ASN
40
n
40
ASN
40
A
LYS
41
n
41
LYS
41
A
GLU
42
n
42
GLU
42
A
ILE
43
n
43
ILE
43
A
PHE
44
n
44
PHE
44
A
LEU
45
n
45
LEU
45
A
ARG
46
n
46
ARG
46
A
GLU
47
n
47
GLU
47
A
LEU
48
n
48
LEU
48
A
ILE
49
n
49
ILE
49
A
SER
50
n
50
SER
50
A
ASN
51
n
51
ASN
51
A
SER
52
n
52
SER
52
A
SER
53
n
53
SER
53
A
ASP
54
n
54
ASP
54
A
ALA
55
n
55
ALA
55
A
LEU
56
n
56
LEU
56
A
ASP
57
n
57
ASP
57
A
LYS
58
n
58
LYS
58
A
ILE
59
n
59
ILE
59
A
ARG
60
n
60
ARG
60
A
TYR
61
n
61
TYR
61
A
GLU
62
n
62
GLU
62
A
SER
63
n
63
SER
63
A
LEU
64
n
64
LEU
64
A
THR
65
n
65
THR
65
A
ASP
66
n
66
ASP
66
A
PRO
67
n
67
PRO
67
A
SER
68
n
68
SER
68
A
LYS
69
n
69
LYS
69
A
LEU
70
n
70
LEU
70
A
ASP
71
n
71
ASP
71
A
SER
72
n
72
SER
72
A
GLY
73
n
73
GLY
73
A
LYS
74
n
74
LYS
74
A
GLU
75
n
75
GLU
75
A
LEU
76
n
76
LEU
76
A
HIS
77
n
77
HIS
77
A
ILE
78
n
78
ILE
78
A
ASN
79
n
79
ASN
79
A
LEU
80
n
80
LEU
80
A
ILE
81
n
81
ILE
81
A
PRO
82
n
82
PRO
82
A
ASN
83
n
83
ASN
83
A
LYS
84
n
84
LYS
84
A
GLN
85
n
85
GLN
85
A
ASP
86
n
86
ASP
86
A
ARG
87
n
87
ARG
87
A
THR
88
n
88
THR
88
A
LEU
89
n
89
LEU
89
A
THR
90
n
90
THR
90
A
ILE
91
n
91
ILE
91
A
VAL
92
n
92
VAL
92
A
ASP
93
n
93
ASP
93
A
THR
94
n
94
THR
94
A
GLY
95
n
95
GLY
95
A
ILE
96
n
96
ILE
96
A
GLY
97
n
97
GLY
97
A
MET
98
n
98
MET
98
A
THR
99
n
99
THR
99
A
LYS
100
n
100
LYS
100
A
ALA
101
n
101
ALA
101
A
ASP
102
n
102
ASP
102
A
LEU
103
n
103
LEU
103
A
ILE
104
n
104
ILE
104
A
ASN
105
n
105
ASN
105
A
ASN
106
n
106
ASN
106
A
LEU
107
n
107
LEU
107
A
GLY
108
n
108
GLY
108
A
THR
109
n
109
THR
109
A
ILE
110
n
110
ILE
110
A
n
111
111
A
n
112
112
A
n
113
113
A
GLY
114
n
114
GLY
114
A
THR
115
n
115
THR
115
A
LYS
116
n
116
LYS
116
A
ALA
117
n
117
ALA
117
A
PHE
118
n
118
PHE
118
A
MET
119
n
119
MET
119
A
GLU
120
n
120
GLU
120
A
ALA
121
n
121
ALA
121
A
LEU
122
n
122
LEU
122
A
GLN
123
n
123
GLN
123
A
ALA
124
n
124
ALA
124
A
GLY
125
n
125
GLY
125
A
ALA
126
n
126
ALA
126
A
ASP
127
n
127
ASP
127
A
ILE
128
n
128
ILE
128
A
SER
129
n
129
SER
129
A
MET
130
n
130
MET
130
A
ILE
131
n
131
ILE
131
A
GLY
132
n
132
GLY
132
A
GLN
133
n
133
GLN
133
A
PHE
134
n
134
PHE
134
A
GLY
135
n
135
GLY
135
A
VAL
136
n
136
VAL
136
A
GLY
137
n
137
GLY
137
A
PHE
138
n
138
PHE
138
A
TYR
139
n
139
TYR
139
A
SER
140
n
140
SER
140
A
ALA
141
n
141
ALA
141
A
TYR
142
n
142
TYR
142
A
LEU
143
n
143
LEU
143
A
VAL
144
n
144
VAL
144
A
ALA
145
n
145
ALA
145
A
GLU
146
n
146
GLU
146
A
LYS
147
n
147
LYS
147
A
VAL
148
n
148
VAL
148
A
THR
149
n
149
THR
149
A
VAL
150
n
150
VAL
150
A
ILE
151
n
151
ILE
151
A
THR
152
n
152
THR
152
A
LYS
153
n
153
LYS
153
A
HIS
154
n
154
HIS
154
A
ASN
155
n
155
ASN
155
A
ASP
156
n
156
ASP
156
A
ASP
157
n
157
ASP
157
A
GLU
158
n
158
GLU
158
A
GLN
159
n
159
GLN
159
A
TYR
160
n
160
TYR
160
A
ALA
161
n
161
ALA
161
A
TRP
162
n
162
TRP
162
A
GLU
163
n
163
GLU
163
A
SER
164
n
164
SER
164
A
SER
165
n
165
SER
165
A
ALA
166
n
166
ALA
166
A
GLY
167
n
167
GLY
167
A
GLY
168
n
168
GLY
168
A
SER
169
n
169
SER
169
A
PHE
170
n
170
PHE
170
A
THR
171
n
171
THR
171
A
VAL
172
n
172
VAL
172
A
ARG
173
n
173
ARG
173
A
THR
174
n
174
THR
174
A
ASP
175
n
175
ASP
175
A
THR
176
n
176
THR
176
A
GLY
177
n
177
GLY
177
A
GLU
178
n
178
GLU
178
A
PRO
179
n
179
PRO
179
A
MET
180
n
180
MET
180
A
GLY
181
n
181
GLY
181
A
ARG
182
n
182
ARG
182
A
GLY
183
n
183
GLY
183
A
THR
184
n
184
THR
184
A
LYS
185
n
185
LYS
185
A
VAL
186
n
186
VAL
186
A
ILE
187
n
187
ILE
187
A
LEU
188
n
188
LEU
188
A
HIS
189
n
189
HIS
189
A
LEU
190
n
190
LEU
190
A
LYS
191
n
191
LYS
191
A
GLU
192
n
192
GLU
192
A
ASP
193
n
193
ASP
193
A
GLN
194
n
194
GLN
194
A
THR
195
n
195
THR
195
A
GLU
196
n
196
GLU
196
A
TYR
197
n
197
TYR
197
A
LEU
198
n
198
LEU
198
A
GLU
199
n
199
GLU
199
A
GLU
200
n
200
GLU
200
A
ARG
201
n
201
ARG
201
A
ARG
202
n
202
ARG
202
A
ILE
203
n
203
ILE
203
A
LYS
204
n
204
LYS
204
A
GLU
205
n
205
GLU
205
A
ILE
206
n
206
ILE
206
A
VAL
207
n
207
VAL
207
A
LYS
208
n
208
LYS
208
A
LYS
209
n
209
LYS
209
A
HIS
210
n
210
HIS
210
A
SER
211
n
211
SER
211
A
GLN
212
n
212
GLN
212
A
PHE
213
n
213
PHE
213
A
ILE
214
n
214
ILE
214
A
GLY
215
n
215
GLY
215
A
TYR
216
n
216
TYR
216
A
PRO
217
n
217
PRO
217
A
ILE
218
n
218
ILE
218
A
THR
219
n
219
THR
219
A
LEU
220
n
220
LEU
220
A
PHE
221
n
221
PHE
221
A
VAL
222
n
222
VAL
222
A
GLU
223
n
223
GLU
223
A
LYS
224
n
224
LYS
224
A
GLU
225
n
225
GLU
225
A
n
226
226
A
n
227
227
A
n
228
228
A
n
229
229
A
author_and_software_defined_assembly
PISA
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
PHE
20
A
N
PHE
20
A
O
PHE
170
A
O
PHE
170
A
N
ARG
173
A
N
ARG
173
A
O
ALA
161
A
O
ALA
161
A
N
SER
164
A
N
SER
164
A
O
VAL
148
A
O
VAL
148
A
N
LYS
153
A
N
LYS
153
A
O
GLY
183
A
O
GLY
183
A
N
LEU
188
A
N
LEU
188
A
O
LEU
89
A
O
LEU
89
A
N
VAL
92
A
N
VAL
92
A
O
ASN
79
A
O
ASN
79
A
N
LEU
80
A
N
LEU
80
A
O
THR
219
A
O
THR
219
1
A
CG
GLU
16
A
CG
GLU
16
1
Y
1
A
CD
GLU
16
A
CD
GLU
16
1
Y
1
A
OE1
GLU
16
A
OE1
GLU
16
1
Y
1
A
OE2
GLU
16
A
OE2
GLU
16
1
Y
1
A
CD
LYS
58
A
CD
LYS
58
1
Y
1
A
CE
LYS
58
A
CE
LYS
58
1
Y
1
A
NZ
LYS
58
A
NZ
LYS
58
1
Y
1
A
CD
LYS
116
A
CD
LYS
116
1
Y
1
A
CE
LYS
116
A
CE
LYS
116
1
Y
1
A
NZ
LYS
116
A
NZ
LYS
116
1
Y
1
A
CG
ASP
127
A
CG
ASP
127
1
Y
1
A
OD1
ASP
127
A
OD1
ASP
127
1
Y
1
A
OD2
ASP
127
A
OD2
ASP
127
1
Y
1
A
CG
GLU
225
A
CG
GLU
225
1
Y
1
A
CD
GLU
225
A
CD
GLU
225
1
Y
1
A
OE1
GLU
225
A
OE1
GLU
225
1
Y
1
A
OE2
GLU
225
A
OE2
GLU
225
1
Y
1
A
MET
1
A
MET
1
1
Y
1
A
PRO
2
A
PRO
2
1
Y
1
A
GLU
3
A
GLU
3
1
Y
1
A
GLU
4
A
GLU
4
1
Y
1
A
THR
5
A
THR
5
1
Y
1
A
GLN
6
A
GLN
6
1
Y
1
A
THR
7
A
THR
7
1
Y
1
A
GLN
8
A
GLN
8
1
Y
1
A
ASP
9
A
ASP
9
1
Y
1
A
GLN
10
A
GLN
10
1
Y
1
A
PRO
11
A
PRO
11
1
Y
1
A
MET
12
A
MET
12
1
Y
1
A
GLU
13
A
GLU
13
1
Y
1
A
GLU
14
A
GLU
14
1
Y
1
A
GLU
15
A
GLU
15
1
Y
1
A
ALA
111
A
ALA
111
1
Y
1
A
LYS
112
A
LYS
112
1
Y
1
A
SER
113
A
SER
113
1
Y
1
A
ARG
226
A
ARG
226
1
Y
1
A
ASP
227
A
ASP
227
1
Y
1
A
LYS
228
A
LYS
228
1
Y
1
A
GLU
229
A
GLU
229
1
Y
1
A
A
N
CA
ILE
ILE
128
128
-0.269
0.020
1.459
1.190
N
1
A
A
CA
C
ILE
ILE
128
128
0.271
0.026
1.525
1.796
N
1
A
TYR
38
-38.16
135.64
1
A
ASP
66
-152.28
84.46
1
A
LYS
100
-36.68
-35.88
1
A
ALA
117
-41.22
-73.45
1
A
LEU
122
-69.41
74.21
1
A
GLN
123
-16.69
-92.81
1
A
ALA
124
-117.51
58.40
1
A
ASP
127
78.77
162.16
1
A
SER
129
-72.87
32.99
1
A
GLN
133
-68.76
1.18
1
A
ALA
166
67.11
-151.27
1
A
ARG
182
-179.12
140.87
1
A
THR
195
-67.78
4.68
43.2
-3.3036
0.0000
0.0000
16.0089
0.0000
-12.7053
0.2893
0.1949
0.1993
2.500
47.163
904
10079
4.8
98.97
0.64
1
1.31
MOLECULAR REPLACEMENT
28.42
0.90
1.11
INTERNAL STRUCTURE
ML
FLAT BULK SOLVENT MODEL
55.173
0.343
2.500
47.163
107
1747
24
0
1616
0.011
1667
1.354
2251
18.967
599
0.081
257
0.007
285
0.3432
0.2717
2.6567
181
2899
98.00
0.3344
0.2371
2.8618
145
3020
99.00
0.2800
0.2089
3.1497
135
2987
99.00
0.2864
0.1745
3.6054
159
2990
100.00
0.2355
0.1479
4.5418
136
3012
99.00
0.2551
0.1792
47.1717
148
2952
98.00
49.7
2.50
56.00
2YI5
10079
0.0
0.08
1
12.20
3.4
99.6
0.52
2.50
2.64
2.30
1
3.5
99.6
refinement
PHENIX
(PHENIX.REFINE)
data reduction
MOSFLM
data scaling
SCALA
phasing
PHASER
HEAT SHOCK PROTEIN HSP 90-ALPHA
Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors.
1
N
N
2
N
N
3
N
N
A
GLN
23
A
GLN
23
HELX_P
A
THR
36
A
THR
36
1
1
14
A
GLU
42
A
GLU
42
HELX_P
A
ASP
66
A
ASP
66
1
2
25
A
PRO
67
A
PRO
67
HELX_P
A
GLY
73
A
GLY
73
5
3
7
A
THR
99
A
THR
99
HELX_P
A
THR
109
A
THR
109
1
4
11
A
GLY
114
A
GLY
114
HELX_P
A
LEU
122
A
LEU
122
1
5
9
A
ILE
131
A
ILE
131
HELX_P
A
GLY
135
A
GLY
135
5
6
5
A
VAL
136
A
VAL
136
HELX_P
A
LEU
143
A
LEU
143
5
7
8
A
GLN
194
A
GLN
194
HELX_P
A
LEU
198
A
LEU
198
5
8
5
A
GLU
199
A
GLU
199
HELX_P
A
GLN
212
A
GLN
212
1
9
14
CHAPERONE
CHAPERONE, ATPASE
HS90A_HUMAN
UNP
1
P07900
1
229
2YI5
1
229
P07900
A
1
1
229
8
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
parallel
A
VAL
17
A
VAL
17
A
ALA
21
A
ALA
21
A
SER
169
A
SER
169
A
THR
174
A
THR
174
A
TYR
160
A
TYR
160
A
SER
164
A
SER
164
A
ALA
145
A
ALA
145
A
LYS
153
A
LYS
153
A
GLY
183
A
GLY
183
A
LEU
190
A
LEU
190
A
THR
88
A
THR
88
A
ASP
93
A
ASP
93
A
ILE
78
A
ILE
78
A
ASN
83
A
ASN
83
A
ILE
218
A
ILE
218
A
LEU
220
A
LEU
220
BINDING SITE FOR RESIDUE YI5 A 1226
Software
11
A
ASN
51
A
ASN
51
11
1_555
A
SER
52
A
SER
52
11
1_555
A
ALA
55
A
ALA
55
11
1_555
A
ASP
93
A
ASP
93
11
1_555
A
GLY
97
A
GLY
97
11
1_555
A
MET
98
A
MET
98
11
1_555
A
PHE
138
A
PHE
138
11
1_555
A
THR
184
A
THR
184
11
1_555
A
VAL
186
A
VAL
186
11
1_555
A
HOH
2030
C
HOH
11
1_555
A
HOH
2056
C
HOH
11
1_555
20
C 2 2 21